
COCH Stock Forecast & Price Target
COCH Analyst Ratings
Bulls say
Envoy Medical is attractive because its fully implanted Acclaim cochlear implant addresses a large unmet need by eliminating the external component that can limit daily use and adoption, while leveraging the ear’s natural anatomy to differentiate it from traditional cochlear implants. Clinical execution has been encouraging: the pivotal trial has surpassed the 6-month follow-up milestone in 56 patients, the first 10 Stage 1 participants showed mean CNC word recognition improving to 53.2% from 39.2% at six months and 15.2% pre-implantation, and no protocol-defined serious adverse events were reported. Although revenue was only $66K in 3Q26 and net loss was $5.2M, the two PMA modules already submitted and the path toward a 2Q27 filing support a credible regulatory runway.
Bears say
Envoy Medical is facing a weak liquidity profile, with cash declining from $19.7M at the end of June 2026 to $14.6M at the end of September 2026 while operating cash outflows remained heavy at ($5.5M) in 2Q26 and ($5.0M) in 3Q26. The company’s dependence on potential warrant exercises is a risk because the outstanding Series A-1 and Series A-2 warrants may need to generate up to $48M of gross proceeds to support operations, yet management believes additional capital may still be needed within the next 12 months absent those exercises. Near-term financial pressure is compounded by the requirement to regain NASDAQ minimum bid-price compliance by November 16, 2026, underscoring a balance-sheet and financing overhang that weakens the outlook.
This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
COCH Analyst Forecast & Price Prediction
Start investing in COCH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Envoy Medical Inc (COCH) Forecast
COCH Analyst Forecast & Price Prediction
Start investing in COCH
Order type
Buy in
Order amount
Est. shares
0 shares